<DOC>
	<DOCNO>NCT01148810</DOCNO>
	<brief_summary>This study determine efficacy , safety , tolerability PK profile BAF312 , novel immunomodulator , polymyositis dermatomyositis patient responsive traditional immunosuppressive and/or corticosteroid therapy . The study consist 12 week , randomize , placebo controlled period , follow another 12 week subject receive BAF312 treatment .</brief_summary>
	<brief_title>Efficacy Tolerability BAF312 Patients With Polymyositis Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<criteria>Patients disease least 3 month study Muscle weakness Received corticosteroid disease modify antirheumatic drug least 3 month study however respond therapy Other idiopathic inflammatory myopathy Myopathy polymyositis dermatomyositis Patients late stage disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Inflammatory muscle disease</keyword>
	<keyword>Muscle weakness</keyword>
	<keyword>Myositis</keyword>
</DOC>